Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
0.9200
-0.0552 (-5.66%)
Nov 16, 2026, 9:56 AM EST - Market open
Decoy Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.17 | 10.71 | 2.43 | 5.9 | 12.11 | 29.21 |
Cash & Short-Term Investments | 8.17 | 10.71 | 2.43 | 5.9 | 12.11 | 29.21 |
Cash Growth | 69.83% | 339.92% | -58.74% | -51.27% | -58.56% | 162.75% |
Receivables | - | - | - | - | 1.61 | - |
Prepaid Expenses | 0.21 | 0.28 | 0.33 | 0.62 | 0.8 | 0.95 |
Other Current Assets | - | - | 0.22 | - | - | - |
Total Current Assets | 8.38 | 10.99 | 2.99 | 6.52 | 14.52 | 30.16 |
Property, Plant & Equipment | 0.39 | 0.04 | - | - | - | - |
Goodwill | - | - | - | - | - | 8.87 |
Long-Term Accounts Receivable | - | - | - | - | - | 1.61 |
Other Long-Term Assets | 0.03 | 0.03 | 0.04 | 0.07 | 0.13 | 0.19 |
Total Assets | 8.79 | 11.06 | 3.02 | 6.59 | 14.65 | 40.83 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.78 | 0.94 | 0.94 | 0.6 | 2.86 | 1.54 |
Accrued Expenses | 0.64 | 0.86 | 0.35 | 0.41 | 1.41 | 0.57 |
Short-Term Debt | - | - | 0.22 | 0.29 | - | - |
Current Unearned Revenue | 2.69 | 3.23 | - | - | - | - |
Other Current Liabilities | 0.14 | 0.14 | - | - | - | - |
Total Current Liabilities | 4.25 | 5.17 | 1.51 | 1.3 | 4.27 | 2.11 |
Total Liabilities | 4.25 | 5.17 | 1.51 | 1.3 | 4.27 | 2.11 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 106.57 | 100.33 | 83.44 | 81.64 | 74.19 | 70.92 |
Retained Earnings | -102.03 | -94.44 | -81.92 | -76.35 | -63.81 | -32.2 |
Total Common Equity | 4.55 | 5.89 | 1.51 | 5.29 | 10.38 | 38.72 |
Shareholders' Equity | 4.55 | 5.89 | 1.51 | 5.29 | 10.38 | 38.72 |
Total Liabilities & Equity | 8.79 | 11.06 | 3.02 | 6.59 | 14.65 | 40.83 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | 0.22 | 0.29 | - | - |
Net Cash (Debt) | 8.17 | 10.71 | 2.21 | 5.61 | 12.11 | 29.21 |
Net Cash Growth | 69.83% | 384.03% | -60.56% | -53.66% | -58.56% | 174.53% |
Net Cash Per Share | 14.60 | 110.45 | 27.59 | - | - | - |
Filing Date Shares Outstanding | 2.39 | 0.53 | - | - | - | 0 |
Total Common Shares Outstanding | 2.39 | 0.53 | - | - | - | 0 |
Working Capital | 4.13 | 5.82 | 1.48 | 5.22 | 10.25 | 28.05 |
Book Value Per Share | 1.91 | 11.07 | - | - | - | 30805.88 |
Tangible Book Value | 4.55 | 5.89 | 1.51 | 5.29 | 10.38 | 29.86 |
Tangible Book Value Per Share | 1.91 | 11.07 | - | - | - | 23752.65 |